Mediators of insulin resistance in women with a history of gestational diabetes mellitus

Overview

About this study

Women with gestational diabetes mellitus (GDM) are likely to have insulin resistance that persists long after pregnancy, resulting in greater risk of developing type 2 diabetes mellitus (T2DM). The study will compare women with and without a previous diagnosis of GDM to determine if women with a history of GDM have abnormal fatty acid metabolism, specifically impaired adipose tissue lipolysis. The study will aim to determine whether women with a history of GDM have impaired pancreatic β-cell function. The study will determine whether women with a history of GDM have tissue specific defects in insulin action, and also identify the effect of a history of GDM on intracellular insulin signaling in subcutaneous adipose tissue.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Women 18 to 50 years of age who had GDM, and glyburide or insulin therapy, during their last pregnancy up to 5 years postpartum. 
  • GDM screening documented
  • Stable weight for ≥ 2 months prior to enrollment with a BMI between 20 and 37 kg/m2 

Exclusion Criteria:

  • Currently pregnant or breastfeeding.
  • Currently smoke
  • Regularly participate in more than 90 min/wk of purposeful physical activity
  • Use of insulin-sensitizing or other medications known to influence glucose or fatty acid metabolism.
  • Women who have had bariatric surgery 
  • Polycystic ovary syndrome
  • T2DM
  • Heart disease
  • Severe lipid disorders
  • Liver disease
  • Renal insufficiency

Inclusion Criteria Control Group:

  • Women 18 to 50 years of age
  • Documented normal glucose tolerance during pregnancy
  • Stable weight for ≥ 2 months prior to enrollment with a BMI between 20 and 37 kg/m2

Exclusion Criteria Control Group:

  • Currently pregnant or breastfeeding.
  • Currently smoke
  • Regularly participate in more than 90 min/wk of purposeful physical activity
  • Use of insulin-sensitizing or other medications known to influence glucose or fatty acid metabolism.
  • Women who have had bariatric surgery 
  • Polycystic ovary syndrome
  • T2DM
  • Heart disease
  • Severe lipid disorders
  • Liver disease
  • Renal insufficiency

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Michael Jensen, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions